Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Dynavax Technologies Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Dynavax Technologies Corporation - Product Pipeline Review - 2014', provides an overview of the Dynavax Technologies Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Dynavax Technologies Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Dynavax Technologies Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Dynavax Technologies Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Dynavax Technologies Corporation's pipeline products Reasons to buy - Evaluate Dynavax Technologies Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Dynavax Technologies Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Dynavax Technologies Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Dynavax Technologies Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Dynavax Technologies Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Dynavax Technologies Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Dynavax Technologies Corporation Snapshot 5 Dynavax Technologies Corporation Overview 5 Key Information 5 Key Facts 5 Dynavax Technologies Corporation - Research and Development Overview 6 Key Therapeutic Areas 6 Dynavax Technologies Corporation - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Dynavax Technologies Corporation - Pipeline Products Glance 10 Dynavax Technologies Corporation - Late Stage Pipeline Products 10 Filing rejected/Withdrawn Products/Combination Treatment Modalities 10 Phase III Products/Combination Treatment Modalities 11 Dynavax Technologies Corporation - Clinical Stage Pipeline Products 12 Phase I Products/Combination Treatment Modalities 12 Dynavax Technologies Corporation - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Dynavax Technologies Corporation - Drug Profiles 15 Hepatitis B Vaccine 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 AZ-1419 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 DV-1179 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 SD-101 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 DV-230 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Recombinant Proteins to Target TLR9 for HPV Infections 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Dynavax Technologies Corporation - Pipeline Analysis 23 Dynavax Technologies Corporation - Pipeline Products by Target 23 Dynavax Technologies Corporation - Pipeline Products by Route of Administration 24 Dynavax Technologies Corporation - Pipeline Products by Molecule Type 25 Dynavax Technologies Corporation - Pipeline Products by Mechanism of Action 26 Dynavax Technologies Corporation - Recent Pipeline Updates 27 Dynavax Technologies Corporation - Dormant Projects 35 Dynavax Technologies Corporation - Discontinued Pipeline Products 36 Discontinued Pipeline Product Profiles 36 Amb a 1-ISS Conjugate 36 Cytovax 36 Dynavax Technologies Corporation - Locations And Subsidiaries 37 Head Office 37 Other Locations & Subsidiaries 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 39 Disclaimer 39
List of Tables Dynavax Technologies Corporation, Key Information 5 Dynavax Technologies Corporation, Key Facts 5 Dynavax Technologies Corporation - Pipeline by Indication, 2014 7 Dynavax Technologies Corporation - Pipeline by Stage of Development, 2014 8 Dynavax Technologies Corporation - Monotherapy Products in Pipeline, 2014 9 Dynavax Technologies Corporation - Filing rejected/Withdrawn, 2014 10 Dynavax Technologies Corporation - Phase III, 2014 11 Dynavax Technologies Corporation - Phase I, 2014 12 Dynavax Technologies Corporation - Preclinical, 2014 13 Dynavax Technologies Corporation - Discovery, 2014 14 Dynavax Technologies Corporation - Pipeline by Target, 2014 23 Dynavax Technologies Corporation - Pipeline by Route of Administration, 2014 24 Dynavax Technologies Corporation - Pipeline by Molecule Type, 2014 25 Dynavax Technologies Corporation - Pipeline Products by Mechanism of Action, 2014 26 Dynavax Technologies Corporation - Recent Pipeline Updates, 2014 27 Dynavax Technologies Corporation - Dormant Developmental Projects,2014 35 Dynavax Technologies Corporation - Discontinued Pipeline Products, 2014 36 Dynavax Technologies Corporation, Subsidiaries 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.